Screener
Acadia Pharmaceuticals ACAD Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Liabilities and stockholders’ equity | ||
| Accounts payable | $44,566 | $10,903 |
| Accrued liabilities | 316,870 | 266,211 |
| Total current liabilities | 361,436 | 277,114 |
| Operating lease liabilities | 59,547 | 40,554 |
| Other long-term liabilities | 15,308 | 19,137 |
| Total liabilities | 436,291 | 336,805 |
| Commitments and contingencies (Note 9) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's total current liabilities?
- Acadia Pharmaceuticals (ACAD) reported total current liabilities of $361.44M in Q2 2026.
- How has Acadia Pharmaceuticals's total current liabilities changed year-over-year?
- Acadia Pharmaceuticals's total current liabilities increased by 9.5% year-over-year, from $330.02M to $361.44M.
- What is the long-term trend for Acadia Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's total current liabilities has grown at a 21.2% compound annual growth rate (CAGR), from $105.97M to $277.11M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Acadia Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude